AbbVie is trading near $262, still 8% below the average analyst target of $285.92, leaving notable upside. The 20‑day EMA has crossed above the 50‑day EMA and RSI sits around 55, indicating a bullish technical backdrop.

Recent headlines place AbbVie on the “Untouchable” short‑seller list and highlight strong blood‑cancer data, reinforcing a positive market narrative. The broader healthcare sector’s late‑day rally adds further momentum to the stock.

AbbVie’s expanding oncology pipeline reduces reliance on legacy revenue streams, supporting a favorable long‑term trajectory. Execution risk remains modest, but the diversified product mix underpins a steady growth outlook.

Daily volume has risen 18% above its 30‑day average, coinciding with a bullish MACD crossover on the 4‑hour chart. The stock remains above its 200‑day moving average, a classic technical signal of sustained uptrend.